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P R E V I E W SFat breakdown: A function for CGI-58 (ABHD5)
provides a new piece of the puzzle
The hydrolysis of fat stored in adipose tissues is crucial for providing energy during fasting and exercise, and dysregulation
of fat breakdownmay contribute to metabolic disease. In this issue of Cell Metabolism, Lass et al. (2006) report that CGI-58/
ABHD5, a lipid-droplet-associated protein that is mutated in a rare disease characterized by excess lipid storage, activates
adipose triglyceride lipase and thus may regulate fat mobilization.Obesity is a disorder of energy balance in
which excess energy, in the form of tri-
acylglycerols (triglycerides, TG), accu-
mulates in white adipose tissue (WAT).
In adipocytes, TG are stored in large, of-
ten solitary cytoplasmic organelles called
lipid droplets, or adiposomes. Their TG
content is determined by the balance of
anabolic and catabolic pathways (Fig-
ure 1). The main anabolic pathway is
the esterfication of glycerol with fatty
acids derived from cellular uptake, de
novo fatty acid synthesis, or intracellular
lipid hydrolysis (lipolysis). The catabolic
pathway involves sequential lipolytic
reactions that ultimately hydrolyze TG
to its simple components, glycerol and
fatty acids. Lipolysis is crucial for mobiliz-
ing these molecules as energy sources
during times of demand such as during
fasting or exercise.
With the discovery of molecules
involved in lipolysis and esterification
during the past several years, a clearer
understanding of the molecular pro-
cesses governing TG storage has
emerged (reviewed in Zechner et al.
[2005]). In particular, several newly iden-
tified molecules have illuminated the lipo-
lytic pathways in WAT and other tissues.
Until recently, hormone-sensitive lipaseCELL METABOLISM : MAY 2006(HSL) was considered to be the sole
lipase of significance in WAT, and its
regulation is well understood. Catechol-
amines, which increase during a fast,
stimulate HSL activity by binding to
b-adrenergic receptors, which in turn
activate stimulatory G proteins, increase
adenylyl cyclase activity and cAMP level,
and activate protein kinase A. This kinase
phosphorylates HSL, thereby activating
the enzyme, and perilipin, an adiposome-
associated protein. Perilipin phospho-
rylation allows HSL to access neutral
lipids in the adiposome core.
For years, it was thought that HSL
meditated most of the breakdown of TG
to monoacylglycerol and fatty acids.
However, gene knockout studies showed
that mice lacking HSL do not accumulate
TG in tissues and are not obese (Roduit
et al., 2001; Haemmerle et al., 2002). In-
stead, they accumulate diacylglycerol
(DG) in tissues, suggesting the major
function of HSL is to hydrolyze DG, and
they have significant residual lipase ac-
tivity in tissues (Haemmerle et al., 2002).
Subsequently, another lipase, adipose
triglyceride lipase (ATGL, also called
desnutrin and iPLA2z), was discovered
by three laboratories (Jenkins et al.,
2004; Villena et al., 2004; Zimmermannet al., 2004). ATGL is expressed in WAT
and other tissues (Villena et al., 2004;
Zimmermann et al., 2004) and hydrolyzes
TG to yield DG and fatty acids (Zimmer-
mann et al., 2004). Evidence suggested
that ATGL accounts for the remaining li-
polytic activity in HSL knockout mice
(Zimmermann et al., 2004). ATGL is upre-
gulated during fasting (Villena et al.,
2004), consistent with a role in fasting-
induced lipolysis, and is expressed in
the cytoplasm and in association with
adiposomes. Unlike HSL, ATGL does
not translocate to the adiposome with
adrenergic stimulation, suggesting that
it is activated by another mechanism
(Zimmermann et al., 2004).
In this issue of Cell Metabolism, Lass
et al. [2006] provide another piece of
the lipolysis puzzle. They report that com-
parative gene identification-58 (CGI-
58)—a human gene transcript that is evo-
lutionarily conserved with C. elegans and
is also known as a/b-hydrolase domain
containing 5 (ABHD5)—activates ATGL
in vitro and may therefore play an impor-
tant role as an activator of the enzyme.
They also show that mutant forms of
CGI-58 fail to activate ATGL and posit
that this biochemical defect contributes
to a rare autosomal recessive disease305
P R E V I E W SFigure 1. Model of anabolic and catabolic pathways that regulate triglyceride (TG) levels in adipocytes
The catabolic pathways involve ATGL, HSL, and monoacylglycerol lipases, which act on TG in a series of re-
actions to yield glycerol and fatty acids. CGI-58, which binds to perilipin and localizes to adiposomes, is an
activator of ATGL. The nature of this activation is unknown. Intermediates of this catabolic pathway may also
be recycled for phospholipids and TG synthesis. The anabolic pathways involve the esterification of fatty acids
to glycerol. Fatty acids, derived from cellular uptake, de novo synthesis, or lipolytic breakdown of intracellular
TG, are ‘‘activated’’ by the addition of a CoA moiety (via the action of acyl CoA synthetases, not shown for
simplicity), and are subsequently esterified to glycerol through the actions of enzymes of the glycerolipid syn-
thesis pathways. Significant amounts of hydrolysis products are normally reesterified (Leibel and Hirsch,
1985), a process that may be regulated. The model proposes that MGAT and DGAT enzymes are involved
in this reesterification. TG, triacylglycerol; DG, diacylglycerol; MG, monacylglycerol; FA, fatty acid; ATGL,
adipose triglyceride lipase; HSL, hormone-sensitive lipase; MGL, monoacylglycerol lipase; DGAT, acyl
CoA:diacylglycerol acyltransferase; MGAT, acyl CoA:monacylglycerol acyltransferase.called Chanarin-Dorfman syndrome
(CDS), which is also called ‘‘neutral lipid
storage disease with ichthyosis.’’ CDS
is characterized by excessive accumu-
lation of TG in the cells of many organs,
including skin, liver, muscle, intestine,
eyes, and ears. The clinical manifes-
tations include ichthyosis (dry, rough,
scaly skin), hepatic steatosis, cataracts,
ataxia, neurosensory hearing loss, and
mental retardation (Dorfman et al.,
1974; Chanarin et al., 1975). In the late
1990s, studies of fibroblasts from CDS
patients showed normal lipase function
in in vitro assays but decreased recycling
of hydrolyzed TG to phospholipids (Igal
and Coleman, 1996).
In 2001, mutations in CGI-58 were
identified in patients with CDS (Lefevre306et al., 2001). CGI-58 is an adiposome-as-
sociated protein (Liu et al., 2004; Subra-
manian et al., 2004) that interacts with
perilipin (Yamaguchi et al., 2004; Subra-
manian et al., 2004). The targeting of
CGI-58 to lipid droplets appears to be
important for its function, as point muta-
tions of CGI-58 in CDS patients weaken
its binding to perilipin and disrupt its re-
cruitment to lipid droplets (Yamaguchi
et al., 2004). CGI-58 resembles lipases
structurally but lacks a key serine in the
canonical lipase catalytic domain, and
its function was unknown.
Lass et al. (2006) showed that CGI-58
acts as an activator of ATGL, but not
HSL, and stimulates lipolysis in vitro. Pu-
rified CGI-58 did not have lipase activity
in vitro, but it stimulated lipolysis whenadded to cytosolic extracts of mouse tis-
sues, including WAT. Importantly, adding
mutant forms of CGI-58 (known to cause
CDS) to ATGL did not increase lipase
activity. In an ELISA, CGI-58 bound to
ATGL; however, coimmunoprecipitation
experiments were not reported. Adipo-
somes isolated from fibroblasts of a
CDS patient, which have a mutant form
of CGI-58, exhibited reduced lipase
activity that was restored by adding
wild-type but not mutant CGI-58. In addi-
tion, expression of functional CGI-58
decreased cellular TG accumulation in
fibroblasts from CDS patients.
These results elucidate a function of
CGI-58 and provide new pieces of the li-
polysis puzzle. CGI-58 activates ATGL,
perhaps the key first step in TG lipolysis.
As usual, new insights raise many new
questions. For example, will the putative
functions for ATGL and CGI-58 be veri-
fied in living organisms? Would mice
lacking ATGL or CGI-58 have increased
TG in WAT and be obese? Conversely,
would mice overexpressing these pro-
teins in WAT be lean? Are HSL and
ATGL the dominant intracellular lipases
for TG and DG in most tissues, or are
TG hydrolase or other lipases (Zechner
et al., 2005) involved? Does CGI-58 act
only in concert with ATGL, or does it
activate other lipases? Do CGI-58 and
ATGL act solely to produce lipids for
release from adipocytes, or do they also
function to provide acylglycerols for
phospholipid synthesis (Igal and Cole-
man, 1998)?
A better molecular understanding of
CGI-58 and how it interacts with ATGL
to promote activity is also needed. For
example, CGI-58 translocates from the
adiposome to the cytoplasm during lipo-
lytic stimulation in 3T3-L1 adipocytes
(Subramanian et al., 2004). It is unclear
how this observation fits with the present
model. Given the intense interest in obe-
sity and its metabolic consequences, it is
likely that answers to these questions will
come rapidly, and the molecular mecha-
nisms of fat breakdown will soon be fully
broken down.
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